# A Study of Sovilnesib in Subjects With Ovarian Cancer

Source: https://onco.cc/trials/nct06084416/  
OnCo record `nct06084416` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Sovilnesib run by Volastra Therapeutics, Inc., now recruiting.

## Summary

A Study of Sovilnesib in Subjects With Ovarian Cancer is a phase 1 interventional study registered as NCT06084416 by Volastra Therapeutics, Inc., with 150 participants planned, started 2024-04-04, primary completion expected 2027-11. Conditions recorded: High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability. Interventions recorded: Sovilnesib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06084416
- Phase: 1
- Setting: A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects With Selected Advanced Solid Tumors
- Sponsor: Volastra Therapeutics, Inc.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT06084416: https://clinicaltrials.gov/study/NCT06084416

## Connected records

- cancers: [High-grade serous ovarian cancer](https://onco.cc/cancers/high-grade-serous-ovarian-cancer/)
- drugs: [Sovilnesib](https://onco.cc/drugs/sovilnesib/)
- companies: [Volastra Therapeutics](https://onco.cc/companies/volastra-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06084416.json